Content deleted Content added
chembox data |
Citation bot (talk | contribs) m Citations: [239]+: last1, first1, last2, first2, last3, first3, last4, first4, last5, first5, last6, first6, last7, first7, last8, first8, last9, first9, title, journal, volume, issue, pages, year, doi, pmc. Tweaked: pmid. Edgar181 |
||
| Line 25: | Line 25: | ||
}} |
}} |
||
'''URB602''' ([1,1'-biphenyl]-3-yl-carbamic acid, cyclohexyl ester) is a compound that has been found to inhibit [[hydrolysis]] of [[monoacyl glycerol]] compounds, such as [[2-arachidonoylglycerol]] (2-AG) and [[2-oleoylglycerol]] (2-OG). It was first described in 2003.<ref name=Tarzia2003>{{cite journal | pmid = 12773040}}</ref> A study performed in 2005 found that the compound had specificity for metabolizing 2-AG over [[anandamide]] (another [[cannabinoid]] ligand) in rat brain presumably by inhibiting the enzyme [[monoacylglycerol lipase]] (MAGL), which is the primary metabolic enzyme of 2-AG.<ref name=Hohmann2005>{{cite journal | doi = 10.1038/nature03658}}</ref> However, subsequent studies have shown that URB602 lacks specificity for MAGL inhibition ''in vitro''.<ref name=Vandevoorde2007>{{cite journal | doi = 10.1038/sj.bjp.0706971}}</ref> |
'''URB602''' ([1,1'-biphenyl]-3-yl-carbamic acid, cyclohexyl ester) is a compound that has been found to inhibit [[hydrolysis]] of [[monoacyl glycerol]] compounds, such as [[2-arachidonoylglycerol]] (2-AG) and [[2-oleoylglycerol]] (2-OG). It was first described in 2003.<ref name=Tarzia2003>{{cite journal | last1 = Tarzia | first1 = G | last2 = Duranti | first2 = A | last3 = Tontini | first3 = A | last4 = Piersanti | first4 = G | last5 = Mor | first5 = M | last6 = Rivara | first6 = S | last7 = Plazzi | first7 = PV | last8 = Park | first8 = C | last9 = Kathuria | first9 = S | title = Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors | journal = Journal of medicinal chemistry | volume = 46 | issue = 12 | pages = 2352–60 | year = 2003 | pmid = 12773040 | doi = 10.1021/jm021119g}}</ref> A study performed in 2005 found that the compound had specificity for metabolizing 2-AG over [[anandamide]] (another [[cannabinoid]] ligand) in rat brain presumably by inhibiting the enzyme [[monoacylglycerol lipase]] (MAGL), which is the primary metabolic enzyme of 2-AG.<ref name=Hohmann2005>{{cite journal | last1 = Hohmann | first1 = Andrea G. | last2 = Suplita | first2 = Richard L. | last3 = Bolton | first3 = Nathan M. | last4 = Neely | first4 = Mark H. | last5 = Fegley | first5 = Darren | last6 = Mangieri | first6 = Regina | last7 = Krey | first7 = Jocelyn F. | last8 = Michael Walker | first8 = J. | last9 = Holmes | first9 = Philip V. | title = An endocannabinoid mechanism for stress-induced analgesia | journal = Nature | volume = 435 | issue = 7045 | pages = 1108 | year = 2005 | pmid = 15973410 | doi = 10.1038/nature03658}}</ref> However, subsequent studies have shown that URB602 lacks specificity for MAGL inhibition ''in vitro''.<ref name=Vandevoorde2007>{{cite journal | last1 = Vandevoorde | first1 = S | last2 = Jonsson | first2 = K-O | last3 = Labar | first3 = G | last4 = Persson | first4 = E | last5 = Lambert | first5 = D M | last6 = Fowler | first6 = C J | title = Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysisin vitro | journal = British Journal of Pharmacology | volume = 150 | issue = 2 | pages = 186 | year = 2007 | pmid = 17143303 | pmc = 2042901 | doi = 10.1038/sj.bjp.0706971}}</ref> |
||
==References== |
==References== |
||
Revision as of 14:59, 18 January 2011
| |
| Names | |
|---|---|
| IUPAC name
Cyclohexyl [1,1'-biphenyl]-3-ylcarbamate
| |
| Other names
[1,1'-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester
| |
| Identifiers | |
3D model (JSmol)
|
|
CompTox Dashboard (EPA)
|
|
| |
| Properties | |
| C19H21NO2 | |
| Molar mass | 295.382 g·mol−1 |
| Appearance | Crystalline solid |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
URB602 ([1,1'-biphenyl]-3-yl-carbamic acid, cyclohexyl ester) is a compound that has been found to inhibit hydrolysis of monoacyl glycerol compounds, such as 2-arachidonoylglycerol (2-AG) and 2-oleoylglycerol (2-OG). It was first described in 2003.[1] A study performed in 2005 found that the compound had specificity for metabolizing 2-AG over anandamide (another cannabinoid ligand) in rat brain presumably by inhibiting the enzyme monoacylglycerol lipase (MAGL), which is the primary metabolic enzyme of 2-AG.[2] However, subsequent studies have shown that URB602 lacks specificity for MAGL inhibition in vitro.[3]
References
- ^ Tarzia, G; Duranti, A; Tontini, A; Piersanti, G; Mor, M; Rivara, S; Plazzi, PV; Park, C; Kathuria, S (2003). "Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors". Journal of medicinal chemistry. 46 (12): 2352–60. doi:10.1021/jm021119g. PMID 12773040.
- ^ Hohmann, Andrea G.; Suplita, Richard L.; Bolton, Nathan M.; Neely, Mark H.; Fegley, Darren; Mangieri, Regina; Krey, Jocelyn F.; Michael Walker, J.; Holmes, Philip V. (2005). "An endocannabinoid mechanism for stress-induced analgesia". Nature. 435 (7045): 1108. doi:10.1038/nature03658. PMID 15973410.
- ^ Vandevoorde, S; Jonsson, K-O; Labar, G; Persson, E; Lambert, D M; Fowler, C J (2007). "Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysisin vitro". British Journal of Pharmacology. 150 (2): 186. doi:10.1038/sj.bjp.0706971. PMC 2042901. PMID 17143303.